Tests empagliflozin in adults with mild to moderate ulcerative colitis
Tests empagliflozin alongside usual care in adults with mild to moderate ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
Key facts
- Where
- Tanta, EgyptSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05610956, who can take part
Where in Egypt
- Gastroenterology and Endoscopy Unit, Internal Medicine Department, Tanta University Hospital.Tanta, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT05610956
- Record updated
- 16 July 2025
- Original description
•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.Read full original descriptionShow less
Clinical Study to Evaluate the Possible Efficacy and Safety of Empagliflozin in Patients With Ulcerative Colitis
•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.
Inclusion: •Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis.
Exclusion: Other inflammatory bowel diseases (CD); History of serious hypersensitivity to empagliflozin or any component of the formulation; Chronic urinary tract infection; Chronic genital infection; Severe renal impairment (eGFR <20 ml/minute/1.73m2) ; Patients on dialysis.